Aim: The aims of this study were to examine treatment outcomes (survival, local control and toxicity) in patients with cervical cancer treated with chemoradiation in stage 1B2-1VA carcinoma of cervix in Department of Radiotherapy, Government Medical College, Kottayam.

Materials and Methods: Between January 2012 to December 2013, 46 patients with cervical cancer were treated with chemoradiation. Case notes were reviewed retrospectively. Acute and late toxicity were recorded, with toxicity graded using the Common Toxicity Criteria Version 4. The mean age was 56 years. All patients were staged with examination under anaesthesia by FIGO staging. The chemotherapy used was cisplatin 40 mg/m2 weekly with radiotherapy. External beam radiotherapy was given to the pelvis (45-46 Gy/23 fractions/4 ^1/2weeks) followed by high dose rate brachytherapy (18 Gyto point A, 9 Gy per fraction weekly in 2 fractions). Optimal dose of radiation (ORT) was defined as a minimal cervical dose exceeding 70 Gy, point A dose of 80–90 Gy, and duration not exceeding 56 days. Optimal dose of radiation was received by 45.7% of patients. Bulky disease, anaemia, advanced stage, non optimal radiation dose and prolonged treatment time affected local failure rate.

Results: The 3-year overall survival rate was 93.5%. The 3-year disease-free survival was 87%.. There were 5 patients (10.9%) with acute toxicities and 21cases (45.8%) of chronic toxicities. Local failure rate was 4.3%

Conclusion: There was a trend towards improved survival and local control with concurrent chemoradiation in this cohort of patients that may become significant with longer follow-up. Patients with anaemia, bulky and locally advanced, cervical cancer treated with weekly cisplatin, teletherapy, and high dose-dose rate brachytherapy have poorer outcomes when treatment duration is prolonged.

Keywords: Cervix carcinoma, chemoradiotherapy, outcome, survival, toxicity.

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Whitney CW, Sause W, Bundy BN, et al.: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J ClinOncol 17 (5): 1339-48
3. Morris M, Eifel PJ, Lu J, et al.: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (15): 1137-43, 1999.
4. Rose PG, Bundy BN, Watkins EB, et al.: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (15): 1144-53, 1999. 
5. Keys HM, Bundy BN, Stehman FB, et al.: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (15): 1154-61, 1999.
6. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J ClinOncol 18 (8): 1606-13, 2000.
7. Tae Wook Kong et.al, Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancerJGynecolOncol Vol. 23, No. 4:235-241
8. Denton AS, Bond SJ, Matthews S, et al. National audit of themanagement and outcome of carcinoma of the cervix treated with radiotherapy in 1993. ClinOncol 2003;12:347-353
9. .Green JA, Kirwan JM, Tierney JF, et al. Systematic review and meta-analysis of randomised trials of concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: better survival and reduced distant recurrence rate. Lancet 2001;358:781-786
10. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin based chemotherapy plus radiotherapy for cervical cancer e a metaanalysis.ClinOncol 2002;14:203-212
11. .Spensley, D. Hunter,  J. E. Livsey, R. Swindelly,  S. E. Davidson. Clinical Outcome for   Chemoradiotherapy in Carcinoma of the Cervix Clinical Oncology (2009) 21: 49-55
12. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcomes of radiation therapy. Int J RadiatOncolBiolPhys 1995;32:1275-1288
13. Mackillop WJ, Bates JHT, O’Sullivan B, et al. The effect of delayin treatment on local control of radiotherapy. Int J RadiatOncolBiolPhys 1996;34:243-250.
14. Tan LT, Zahra M. Long term survival and late toxicity after chemo-radiotherapy for cervical cancer e the Addenbrooke’s experience. ClinOncol 2008;20:358-364
15. Mackillop WJ, Bates JHT, O’Sullivan B, et al. The effect of delay in treatment on local control of radiotherapy. Int J RadiatOncolBiolPhys 1996;34:243-250.
16. Girinsky T, Rey A, Roche B, et al. Overall treatment time in advanced cervical carci-nomas: a critical parameter in treatment outcome. Int J RadiatOncolBiolPhys 1993;27:1051-1056
17. Meenakshi Mittal, ,Bikramjit Singh, , Rajesh Vashistha, Original article: Effectiveness of two different HDR brachytherapy regimens with the same BED value in cervical Department of Radiotherapy, 1.M.D. Oswal Cancer Institute & Research Foundation, Ludhiana (Pb), India,2.Medical Physics Division, Department of Radiation Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Centers, Pittsburgh, PA, USA, 3Department of Physics, University of Mumbai (MH), India, 4Physics Division, Bhabha Atomic Research Centre, Mumbai (MH), India
18. H Maduro,E.Prasetal :Acute and long term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer December 2003,Volume 29,(6 )461-576.

Dr Manoj .S

Assistant Professor, Department of Radiotherapy

Government Medical College, Kottayam, India